PCSK9 Inhibition After Heart Transplantation

Vasculopathy Clinical Trial

Official title:
PCSK9 Inhibition After Heart Transplantation

Status Enrolling by invitation

Clinical Trial Summary

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03537742
Study type	Interventional
Source	Stanford University
Contact
Status	Enrolling by invitation
Phase	Phase 2
Start date	May 13, 2019
Completion date	February 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00384540` - Cardiac Allograft Vasculopathy and Dobutamine Stress Echocardiography / Brain Natriuretic Peptide Coupling	N/A
Recruiting	`NCT06392347` - Evaluation of Accelerated Sampling Techniques for Vessel Wall Imaging
Not yet recruiting	`NCT04051086` - Quantification of Elastin Markers Synthesis in Williams-Beuren Syndrome and 7q11.23 Micro-duplication Syndrome	N/A
Completed	`NCT05485467` - The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients
Not yet recruiting	`NCT05251129` - Statin InTensity to Prevent Coronary Artery Vasculopathy After Heart Transplantation	N/A